sodium chlorite (HM-001)
/ HOIST
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
November 09, 2024
Development of a Novel Intravesical Therapy Using Sodium Chlorite (HM-001) for Bladder Cancer: Transition from Preclinical to Clinical trial
(EMUC 2024)
- "Furthermore, the fact that it is effective against high-grade and low-grade PDX-derived bladder cancer tissues indicates that it may be widely applicable to patients with NMIBC. A Phase I/IIa, multi-center, open-label, investigator-initiated study of HM-001 is currently underway in patients with non-muscle invasive bladder cancer undergoing TURBT."
Preclinical • Bladder Cancer • Genito-urinary Cancer • Oncology • Solid Tumor
March 06, 2024
Development of HM-001 as a therapeutic drug for non-muscle invasive bladder cancer
(AACR 2024)
- "HM-001 is a drug containing sodium chlorite as the active ingredient that is being developed as a drug for non-muscle invasive bladder cancer (NMIBC), and is currently undergoing physician-led clinical trials...In particular, low-grade forms are restricted to low- and intermediate-risk groups. The results of this study show that HM-001 is effective not only for high-risk (including CIS) NMIBC but also for low- and intermediate-risk (low-grade) NMIBC."
Bladder Cancer • Genito-urinary Cancer • Oncology • Solid Tumor
1 to 2
Of
2
Go to page
1